Evidence map›Paper›PMID 35602497›Full record

SynthesisFrontiers in medicine2022

Overview of the RGD-Based PET Agents Use in Patients With Cardiovascular Diseases: A Systematic Review.

Matthieu Dietz, Christel H Kamani, Vincent Dunet, Stephane Fournier, Vladimir Rubimbura, Nathalie Testart Dardel, Ana Schaefer, Mario Jreige, Sarah Boughdad, Marie Nicod Lalonde and 4 more

Erratum issuedOpen access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Journal of the American Heart Association · 2025
    Article
  3. Article
  4. Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025
    Review
  5. Article
  6. Targeted imaging of angiogenesis post-myocardial infarction predicts development of heart failure.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  7. Review
  8. Comparison of integrin αEuropean journal of hybrid imaging · 2023
    Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Matthieu DietzNuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
Christel H KamaniNuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
Vincent DunetDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.
Stephane FournierCardiology Department, Lausanne University Hospital, Lausanne, Switzerland.
Vladimir RubimburaCardiology Department, Lausanne University Hospital, Lausanne, Switzerland.
Nathalie Testart DardelNuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
Ana SchaeferNuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
Mario JreigeDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.
Sarah BoughdadNuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
Marie Nicod LalondeNuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
Niklaus SchaeferNuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
Nathan MewtonINSERM U1060, CarMeN Laboratory, University of Lyon, Lyon, France.
John O PriorNuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
Giorgio TregliaNuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
University of Lausanne · CHLaboratoire CarMeN · FRUniversità della Svizzera italiana · CHUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies using arginine-glycine-aspartate (RGD)-PET agents in cardiovascular diseases have been recently published. The aim of this systematic review was to perform an updated, evidence-based summary about the role of RGD-based PET agents in patients with cardiovascular diseases to better address future research in this setting. Original articles within the field of interest reporting the role of RGD-based PET agents in patients with cardiovascular diseases were eligible for inclusion in this systematic review. A systematic literature search of PubMed/MEDLINE and Cochrane library databases was performed until October 26, 2021. Literature shows an increasing role of RGD-based PET agents in patients with cardiovascular diseases. Overall, two main topics emerged: the infarcted myocardium and atherosclerosis. The existing studies support that α

Indexed as

angiogenesisatherosclerosiscardiovascular diseasesmyocardial infarctionpositron emission tomographyRGDαvβ3 integrin

Identifiers

PMID35602497
PMCPMC9120643
OpenAlexW4229026683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.